Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC) Meeting Abstract

  

Authors:	Cleary, J. M.; Voss, M. H.; Meric-Bernstam, F.; Hierro, C.; Heist, R. S.; Ishii, N.; Kirpicheva, Y.; Nicolas-Metral, V.; Pokorska-Bocci, A.; Vaslin, A.; Venetz, W.; Zanna, C.; Flaherty, K.; Tabernero, J.; Baselga, J.
Abstract Title:	Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC)
Meeting Title:	2018 Gastrointestinal Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	36
Issue:	4 Suppl.
Meeting Dates:	2018 Jan 18-20
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2018-02-01
Language:	English
ACCESSION:	WOS:000436174100428
DOI:	10.1200/JCO.2018.36.4_suppl.447
PROVIDER:	wos
Notes:	Meeting Abstract: 447 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/169254